Sakai S, Koide T, Ito Y, Tei K, Deguchi T, Matsuda S, Kato N, Ban Y, Nishiura T
Hinyokika Kiyo. 1986 May;32(5):661-5.
Using a polyamine-test enzyme kit, the urine polyamine concentration was determined in 74 patients with malignant urological disease (12 with renal cell cancer, 13 with pelvic-ureter cancer, 24 with bladder cancer and 25 with prostate cancer), 7 patients with BPH, 20 patients with benign urological disease and 20 normal subjects. The urine polyamine level was significantly elevated in all the patients with any malignant urological disease compared to normal subjects. It was also significantly high in the patients with BPH. Defining the mean +/- 3SD (= 50 mumole/g Cr.) of 20 normal subjects as an upper limit, slightly higher levels not exceeding 100 mumol/g Cr. were frequently observed in the patients with BPH or with benign urological disease. Setting the upper limit at 100 mumole/g Cr., the positive rate amounted to 33% (low stage 17%) in renal cell cancer, 23% (low stage 14%) in pelvic ureter cancer, 13% (low stage 0%) in bladder cancer and 4% (low stage 0%) in prostate cancer. The positive rate was low especially in low stage cases.
使用多胺检测试剂盒,对74例泌尿系统恶性疾病患者(12例肾细胞癌、13例肾盂输尿管癌、24例膀胱癌和25例前列腺癌)、7例良性前列腺增生症患者、20例泌尿系统良性疾病患者及20名正常受试者的尿液多胺浓度进行了测定。与正常受试者相比,所有泌尿系统恶性疾病患者的尿液多胺水平均显著升高。良性前列腺增生症患者的尿液多胺水平也显著升高。将20名正常受试者的平均值±3标准差(=50微摩尔/克肌酐)定义为上限,在良性前列腺增生症患者或泌尿系统良性疾病患者中经常观察到略高于该上限但不超过100微摩尔/克肌酐的水平。将上限设定为100微摩尔/克肌酐时,肾细胞癌的阳性率为33%(低分期为17%),肾盂输尿管癌为23%(低分期为14%),膀胱癌为13%(低分期为0%),前列腺癌为4%(低分期为0%)。尤其是在低分期病例中,阳性率较低。